alexa
Reach Us +1-217-403-9671
Cell Therapy Regulations - A Critical Factor In Translational Medicine | 8299
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Cell therapy regulations - a critical factor in translational medicine

International Conference and Exhibiton on Pharmaceutical Regulatory Affairs

Beate Wagner and Reinhard Henschler

ScientificTracks Abstracts: JBB

DOI: 10.4172/0975-0851.1000107

Abstract
T he current state of cell therapy regulations in Europe is presented from the perspective of a manufacturer in a university hospital who also is a member of the hospital ́s recently founded Interdisciplinary Centre of Cell Th erapy (IZZTKUM). An overview of Good Manufacturing Practice (GMP) and other standards will be given, focusing on the manufacture of sterile medicinal products in a class 100 (A) cleanroom. Links to the application of these products in clinical trials according to Good Clinical Practice (GCP) will be identifi ed. Measures for quality assurance such as accreditation are considered useful tools to demonstrate compliance with laws and regulations. Recent developments in cell therapy ? specifi cally the Advanced Th erapy Medicinal Products (ATMPs) - have prompted a cascade of new regulations which will be outlined. Conversely the latter have challenged current methods and concepts such as testing product identity or sterility aft er culture and other manipulation procedures. Th e large spectrum of methods required for manufacturing and quality control of ATMPs results in the involvement of other partners and the need of written agreements. Coping with all these standards and regulations remains critical in the implementation of new options in cell therapy
Biography
Beate Wagner earned her doctoral degree from Ruprecht Karls University of Heidelberg. She is a specialist in internal medicine and transfusion medicine and works as Senior Consultant and laboratory director in the Department of Transfusion Medicine & Hemostaseology, University Hospitals of Munich. At 2 sites she implemented cleanroom operation and sterile manufacture, which she is the Quali fi ed Person of. She also is a member of the hospital ́s recently founded Interdisciplinary Centre of Cell Therapy (IZZT KUM )
Top